Compugen Ltd. (NASDAQ:CGEN) Short Interest Down 18.1% in October

Compugen Ltd. (NASDAQ:CGEN - Get Free Report) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 1,270,000 shares, a decrease of 18.1% from the October 15th total of 1,550,000 shares. Based on an average trading volume of 225,400 shares, the short-interest ratio is currently 5.6 days.

Institutional Trading of Compugen

A number of hedge funds have recently modified their holdings of the company. Rothschild Investment LLC bought a new position in Compugen in the second quarter worth $380,000. ARK Investment Management LLC lifted its holdings in shares of Compugen by 4.7% during the 2nd quarter. ARK Investment Management LLC now owns 1,088,271 shares of the biotechnology company's stock worth $1,850,000 after acquiring an additional 48,979 shares during the period. Squarepoint Ops LLC boosted its position in shares of Compugen by 23.4% during the 2nd quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company's stock valued at $144,000 after acquiring an additional 16,253 shares in the last quarter. Secure Asset Management LLC bought a new stake in Compugen in the second quarter valued at about $69,000. Finally, Joel Isaacson & Co. LLC raised its position in Compugen by 136.4% in the third quarter. Joel Isaacson & Co. LLC now owns 52,000 shares of the biotechnology company's stock worth $94,000 after purchasing an additional 30,000 shares in the last quarter. Institutional investors own 12.22% of the company's stock.

Compugen Stock Performance

Shares of NASDAQ:CGEN traded down $0.08 during midday trading on Friday, hitting $1.41. 441,994 shares of the stock were exchanged, compared to its average volume of 407,292. The company has a market capitalization of $125.82 million, a PE ratio of 70.50 and a beta of 2.64. The business's fifty day simple moving average is $1.75 and its two-hundred day simple moving average is $1.87. Compugen has a 52-week low of $0.61 and a 52-week high of $3.03.

Compugen (NASDAQ:CGEN - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.21 by ($0.20). The firm had revenue of $17.13 million during the quarter, compared to the consensus estimate of $17.67 million. Compugen had a net margin of 2.67% and a return on equity of 2.62%. During the same period in the prior year, the business earned ($0.11) EPS. As a group, equities analysts anticipate that Compugen will post 0.07 EPS for the current year.

Analyst Ratings Changes

Separately, StockNews.com raised Compugen from a "hold" rating to a "buy" rating in a report on Thursday, August 15th.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.